[go: up one dir, main page]

ZA200701057B - Crystalline form of a biphenyl compound - Google Patents

Crystalline form of a biphenyl compound

Info

Publication number
ZA200701057B
ZA200701057B ZA200701057A ZA200701057A ZA200701057B ZA 200701057 B ZA200701057 B ZA 200701057B ZA 200701057 A ZA200701057 A ZA 200701057A ZA 200701057 A ZA200701057 A ZA 200701057A ZA 200701057 B ZA200701057 B ZA 200701057B
Authority
ZA
South Africa
Prior art keywords
crystalline form
biphenyl compound
biphenyl
compound
crystalline
Prior art date
Application number
ZA200701057A
Other languages
English (en)
Inventor
Robert S Chao
Colson Pierre-Jean
Rapta Miroslav
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of ZA200701057B publication Critical patent/ZA200701057B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200701057A 2004-08-16 2007-02-05 Crystalline form of a biphenyl compound ZA200701057B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60180504P 2004-08-16 2004-08-16

Publications (1)

Publication Number Publication Date
ZA200701057B true ZA200701057B (en) 2008-08-27

Family

ID=35687428

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200701057A ZA200701057B (en) 2004-08-16 2007-02-05 Crystalline form of a biphenyl compound

Country Status (25)

Country Link
US (4) US7521558B2 (xx)
EP (1) EP1778672B1 (xx)
JP (2) JP5032990B2 (xx)
KR (1) KR101363352B1 (xx)
CN (1) CN101006077B (xx)
AR (1) AR051003A1 (xx)
AU (1) AU2005277601B2 (xx)
BR (1) BRPI0514413C1 (xx)
CA (1) CA2575874C (xx)
DK (1) DK1778672T3 (xx)
ES (1) ES2400958T3 (xx)
HR (1) HRP20130192T1 (xx)
IL (1) IL180853A (xx)
MA (1) MA28825B1 (xx)
MX (1) MX2007001688A (xx)
MY (1) MY141224A (xx)
NO (1) NO338770B1 (xx)
NZ (1) NZ552796A (xx)
PL (1) PL1778672T3 (xx)
PT (1) PT1778672E (xx)
RU (1) RU2381223C2 (xx)
SI (1) SI1778672T1 (xx)
TW (1) TWI374883B (xx)
WO (1) WO2006023454A1 (xx)
ZA (1) ZA200701057B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
CN101522622A (zh) * 2006-10-04 2009-09-02 辉瑞有限公司 作为肾上腺素能激动剂和毒蕈碱拮抗剂的磺胺衍生物
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
CA2758353C (en) * 2009-04-14 2017-06-06 Dean David Edney Process for the preparation of a biphenyl-2-ylcarbamic acid ester
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PL2599778T3 (pl) 2009-04-23 2018-01-31 Theravance Respiratory Co Llc Związki diamidowe mających działanie antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta 2
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
IN2014CN02850A (xx) * 2011-10-31 2015-07-03 Glaxosmithkline Intellectual Property Ltd
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CN105142673B8 (zh) 2012-12-18 2018-02-16 阿尔米雷尔有限公司 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TW201835041A (zh) 2017-02-17 2018-10-01 印度商托仁特生技有限公司 具β-腎上腺素促效劑及抗蕈毒活性化合物
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
US20240300919A1 (en) * 2021-02-19 2024-09-12 Gbr Laboratories Private Limited A process for preparing batefenterol and intermediates thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS596860B2 (ja) * 1975-05-19 1984-02-15 オオツカセイヤク カブシキガイシヤ ５−〔（２−アルキルアミノ−１−ヒドロキシ）アルキル〕カルボスチリル誘導体の製造法
TW297025B (xx) * 1992-02-14 1997-02-01 Squibb & Sons Inc
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
EP1235802B1 (en) 1999-12-07 2005-07-13 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2004356517A (ja) 2003-05-30 2004-12-16 Ebara Corp 基板洗浄装置及び基板洗浄方法
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
WO2005080375A1 (en) * 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound

Also Published As

Publication number Publication date
BRPI0514413B1 (pt) 2019-04-16
HK1106227A1 (en) 2008-03-07
MX2007001688A (es) 2007-04-23
MY141224A (en) 2010-03-31
IL180853A (en) 2014-03-31
DK1778672T3 (da) 2013-03-25
JP2008513358A (ja) 2008-05-01
ES2400958T3 (es) 2013-04-15
CA2575874C (en) 2012-10-09
US8476299B2 (en) 2013-07-02
US20130289281A1 (en) 2013-10-31
EP1778672A1 (en) 2007-05-02
US20060035931A1 (en) 2006-02-16
CA2575874A1 (en) 2006-03-02
JP5032990B2 (ja) 2012-09-26
HRP20130192T1 (hr) 2013-04-30
AR051003A1 (es) 2006-12-13
US7521558B2 (en) 2009-04-21
US20090221638A1 (en) 2009-09-03
US8754223B2 (en) 2014-06-17
BRPI0514413A (pt) 2008-06-10
SI1778672T1 (sl) 2013-04-30
KR101363352B1 (ko) 2014-02-14
NZ552796A (en) 2010-09-30
NO338770B1 (no) 2016-10-17
AU2005277601A1 (en) 2006-03-02
CN101006077B (zh) 2012-04-25
KR20070057832A (ko) 2007-06-07
PT1778672E (pt) 2013-02-25
EP1778672B1 (en) 2012-12-19
US8101766B2 (en) 2012-01-24
TWI374883B (en) 2012-10-21
RU2007109598A (ru) 2008-09-27
RU2381223C2 (ru) 2010-02-10
IL180853A0 (en) 2007-07-04
US20120283289A1 (en) 2012-11-08
PL1778672T3 (pl) 2013-05-31
WO2006023454A1 (en) 2006-03-02
JP2012121929A (ja) 2012-06-28
TW200613296A (en) 2006-05-01
NO20071307L (no) 2007-04-11
CN101006077A (zh) 2007-07-25
MA28825B1 (fr) 2007-08-01
BRPI0514413C1 (pt) 2021-05-25
AU2005277601B2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
ZA200701057B (en) Crystalline form of a biphenyl compound
IL185471A0 (en) Crystalline forms of a biphenyl compound
ZA200708071B (en) Crystalline form of a quinolinone-carboxamide compound
IL206109A (en) Cinnamide compound
LT3281939T (lt) Derinys, apimantis stabilų 4-oksochinolino junginio kristalą
GB0504995D0 (en) Use of a compound
GB0408771D0 (en) Compound
IL187981A0 (en) Crystalline forms of a pyrrolotriazine compound
ZA200900208B (en) Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
IL183825A0 (en) Crystalline forms of a factor xa inhibitor
ZA200806859B (en) Novel crystalline compounds
ZA200609845B (en) Cinnamide compound
GB0413738D0 (en) Novel organofluorine compounds
IL177451A0 (en) Crystalline forms of a pharmaceutical compound
ZA200706428B (en) Crystalline ACAT inhibitor
GB0522829D0 (en) Use of a compound
GB0515818D0 (en) A novel compound
HK1128023A (en) Crystalline forms of a dimethylphenyl compound
ZA200704263B (en) Crystalline forms of a factor Xa inhibitor
GB0413769D0 (en) Novel compound
GB0413770D0 (en) Novel compound
GB0413763D0 (en) Novel compound
GB0413764D0 (en) Novel compound
GB0413765D0 (en) Novel compound
GB0413768D0 (en) Novel compound